Fenofibrate: Indications and Dosing
Fenofibrate is indicated as an adjunct to diet for reducing elevated LDL-C, Total-C, triglycerides, and Apo B while increasing HDL-C in primary hypercholesterolemia or mixed dyslipidemia, and for treating severe hypertriglyceridemia (triglycerides ≥500 mg/dL), with critical dosing adjustments required based on renal function. 1
Primary Indications
Fenofibrate serves two main therapeutic purposes:
- Primary hypercholesterolemia or mixed dyslipidemia: Standard dose of 160 mg once daily with meals 1
- Severe hypertriglyceridemia: Initial dose ranges from 54 mg to 160 mg once daily, with a maximum of 160 mg daily 1
Important Limitation
Fenofibrate has not been shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus 1. The ACC/AHA guidelines reflect this uncertainty, stating fenofibrate may only be considered concomitantly with low- or moderate-intensity statins when benefits from ASCVD risk reduction or triglyceride lowering (when triglycerides are ≥500 mg/dL) outweigh potential risks—a Class IIb recommendation with Level C evidence 2.
Critical Dosing Adjustments for Renal Impairment
Renal function assessment is mandatory before initiating fenofibrate, at 3 months, and every 6 months thereafter using both serum creatinine and eGFR 2.
Specific Renal Dosing Algorithm:
- eGFR ≥60 mL/min/1.73 m²: Standard dosing (54-160 mg daily depending on indication)
- eGFR 30-59 mL/min/1.73 m²: Maximum dose 54 mg once daily 2, 1
- eGFR <30 mL/min/1.73 m²: Contraindicated—do not use 2, 1
- Dialysis patients: Contraindicated 1
If eGFR persistently decreases to <30 mL/min/1.73 m² during follow-up, discontinue fenofibrate immediately 2.
The KDOQI guidelines reinforce this caution, noting that most randomized trials excluded individuals with eGFR <45 mL/min/1.73 m², and fibrates were associated with acute eGFR reductions and increased hospitalization risk for creatinine elevation in CKD patients 3.
Administration Details
- Take with meals to optimize absorption 1
- Multiple fenofibrate formulations exist—consult manufacturer's prescribing information for specific products 2
Geriatric Considerations
Dose selection in elderly patients must be based entirely on renal function 1. Since fenofibric acid is substantially excreted by the kidney and elderly patients have higher rates of renal impairment, calculate eGFR before prescribing. Elderly patients with normal renal function require no dose modification, but those with any degree of impairment follow the renal dosing algorithm above 1.
Critical Safety Monitoring
Beyond renal function, monitor for:
- Hepatotoxicity: Check baseline and periodic ALT, AST, and total bilirubin; discontinue if liver injury develops 1
- Myopathy/Rhabdomyolysis: Risk increases with statin combination (especially gemfibrozil, which should never be combined with statins), in elderly patients, diabetes, renal failure, or hypothyroidism 2, 1. Recent case reports document fenofibrate-associated rhabdomyolysis even without statins, particularly in CKD patients receiving unadjusted doses 4, 5
- Creatinine elevation: Fenofibrate reversibly increases serum creatinine, often within weeks of initiation 6, 7, 8. This may reflect reduced renal plasma flow rather than true nephrotoxicity, but increases ≥30% warrant treatment discontinuation 6
Common Pitfalls to Avoid
- Failing to calculate eGFR before prescribing: This is the most critical error, as unadjusted dosing in renal impairment significantly increases adverse event risk 5, 9
- Combining with gemfibrozil and statins: Gemfibrozil should never be initiated in patients on statin therapy due to increased rhabdomyolysis risk 2
- Ignoring nonspecific symptoms in CKD patients: Nausea, poor appetite, or unexplained renal deterioration after fenofibrate exposure should prompt immediate CK and myoglobin measurement, as classic myalgia may be absent 5
- Using in active liver disease or gallbladder disease: Both are absolute contraindications 1